Contento de compartirles que estoy cerrando el año con la publicación de mi primer trabajo original como primer autor. Muchas gracias a todo el equipo por su gran colaboración.
https://t.co/6SIP4IYVDs
Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: https://t.co/ZCfkG7tpBI
In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no additional benefit over semaglutide.
#ESCCongress#WCCardio
https://t.co/0KyzTwgJmi
Presented at #ESCCongress:
In patients with an acute coronary syndrome, stopping aspirin early after PCI and using P2Y12 inhibitor monotherapy was not noninferior to dual therapy with respect to risk of death or ischemic events but did reduce bleeding events. Full NEO-MINDSET trial: https://t.co/UDMGkYaIQg
@escardio
Presented at #ESCCongress:
In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Full TARGET-FIRST trial results: https://t.co/mbENNhPZ7G
@escardio
In patients without atrial arrhythmia recurrence after AF ablation, discontinuing oral anticoagulant therapy reduced the composite risk of stroke, systemic embolism, and major bleeding compared with continued therapy. 🧵
#ESCCongress#WCCardio
https://t.co/Ds6HJKDsno
El INCMNSZ felicita a la dra. Dheni Aidé Fernández Camargo y a los dres. Jesús Alejandro Romero Águila y Luis André Fortanell Meza por su elección como jefa y jefes de Residentes de Medicina Interna para el periodo 2025-2026.